Equities research analysts expect Curis, Inc. (NASDAQ:CRIS) to post $2.03 million in sales for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Curis’ earnings. The highest sales estimate is $2.15 million and the lowest is $1.90 million. Curis reported sales of $2.36 million in the same quarter last year, which indicates a negative year over year growth rate of 14%. The company is scheduled to announce its next earnings results on Thursday, March 8th.
According to Zacks, analysts expect that Curis will report full year sales of $2.03 million for the current financial year, with estimates ranging from $8.50 million to $8.79 million. For the next fiscal year, analysts expect that the business will report sales of $9.69 million per share, with estimates ranging from $8.97 million to $10.40 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side analysts that cover Curis.
A number of equities research analysts have recently weighed in on CRIS shares. Zacks Investment Research upgraded shares of Curis from a “sell” rating to a “hold” rating in a research report on Monday, October 16th. Guggenheim started coverage on shares of Curis in a research report on Monday, October 23rd. They issued a “buy” rating and a $7.00 price target for the company. Two analysts have rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $6.50.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. raised its position in shares of Curis by 1.6% in the second quarter. Goldman Sachs Group Inc. now owns 119,638 shares of the biotechnology company’s stock valued at $226,000 after buying an additional 1,880 shares in the last quarter. The Manufacturers Life Insurance Company raised its position in Curis by 8.8% during the second quarter. The Manufacturers Life Insurance Company now owns 100,023 shares of the biotechnology company’s stock valued at $190,000 after purchasing an additional 8,102 shares in the last quarter. Voya Investment Management LLC raised its position in Curis by 21.8% during the second quarter. Voya Investment Management LLC now owns 68,138 shares of the biotechnology company’s stock valued at $129,000 after purchasing an additional 12,207 shares in the last quarter. Royal Bank of Canada raised its position in Curis by 4.9% during the second quarter. Royal Bank of Canada now owns 956,717 shares of the biotechnology company’s stock valued at $1,808,000 after purchasing an additional 44,421 shares in the last quarter. Finally, Northern Trust Corp raised its position in Curis by 3.8% during the second quarter. Northern Trust Corp now owns 1,334,679 shares of the biotechnology company’s stock valued at $2,523,000 after purchasing an additional 49,310 shares in the last quarter. Institutional investors own 56.09% of the company’s stock.
Shares of Curis (NASDAQ CRIS) opened at $0.55 on Tuesday. The company has a debt-to-equity ratio of 1.24, a current ratio of 5.15 and a quick ratio of 5.15. Curis has a 1 year low of $0.48 and a 1 year high of $3.22. The firm has a market cap of $90.26, a P/E ratio of -1.41 and a beta of 1.56.
Curis Company Profile
Curis, Inc is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.